← Back to Search

GLP-1 Agonist

Semaglutide 1MG Injection [Ozempic] for Spinal Cord Injury

Phase 4
Waitlist Available
Research Sponsored by James J. Peters Veterans Affairs Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, week 13, week 26
Awards & highlights

Study Summary

This trial is testing whether a new medication can help people with spinal cord injury by improving glycemic control and inducing weight loss.

Eligible Conditions
  • Spinal Cord Injury
  • Insulin Resistance
  • Prediabetes
  • Obesity

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, week 13, week 26
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, week 13, week 26 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Body Weight
Homeostatic Model Assessment of Beta-Cell Function (HOMA-B)
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
Secondary outcome measures
Body Fat
Glycated Hemoglobin (HbA1C)

Trial Design

2Treatment groups
Experimental Treatment
Group I: Semaglutide 1MG Injection [Ozempic]Experimental Treatment1 Intervention
20 subjects will be randomized to receive once weekly injection of Semaglutide (Ozempic1mg) for 26 weeks.
Group II: No InterventionExperimental Treatment1 Intervention
10 subjects will be randomized to receive no intervention for 26 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Semaglutide 1MG Injection [Ozempic]
2018
Completed Phase 4
~10

Find a Location

Who is running the clinical trial?

James J. Peters Veterans Affairs Medical CenterLead Sponsor
57 Previous Clinical Trials
2,895 Total Patients Enrolled
Kessler Institute for RehabilitationIndustry Sponsor
22 Previous Clinical Trials
1,160 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Once Weekly GLP-1 in Persons With Spinal Cord Injury
William A. Bauman, M.D. 2018. "Once Weekly GLP-1 in Persons With Spinal Cord Injury". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03292315.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top